Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Boditech Med Inc. (206640.KQ)
Chuncheon-si, KR
Founded in 1998 and headquartered in Chuncheon, South Korea, Boditech Med Inc. specializes in the development of in-vitro diagnostic solutions and reagents. The company's diverse product portfolio includes a range of advanced immunoassay analyzers designed to quantify analytes in various biological samples like blood, urine, and other body fluids. Key offerings include the ichroma II, an automated or semi-automated system for precise analyte measurement; AFIAS-6 and AFIAS-1, automated fluorescent immunoassay systems also designed for accurate quantification of targeted analytes; and the ichroma-50, an automatic immunoassay analyzer that determines analyte concentrations in bodily fluids. Additionally, the ichroma M2 is a portable analyzer suited for centralized hospital laboratories and physician's clinics, compatible with in-vitro diagnostic immunofluorescent assay kits for screening, monitoring, and routine examinations. Beyond these, Boditech Med also provides specialized diagnostic instruments such as the Ichroma TRIAS Reader, which measures targeted analyte concentration from diverse samples including blood, nasal, and nasopharyngeal swabs; the Hemochroma PLUS for quantitative total hemoglobin testing in blood; the i-chamber, an auxiliary component for ichroma systems; and the HandyRay, an innovative laser device facilitating needle-free capillary blood sampling. These diagnostic solutions address a broad spectrum of medical fields, including cardiac health, oncology, diabetes management, hormone analysis, infection, infectious diseases, gastrointestinal issues, and rheumatoid arthritis. Boditech Med Inc. distributes its products globally through a network of approximately 100 sales agencies.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.92% | -3.02% | -6.50% | -17.94% | -21.76% | -17.70% | -32.82% | -5.53% | -45.89% | -59.52% | -39.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-10 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+17.3% ★ Q1'26: +9.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-12.1% Q1'26: +40.0% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+4.9% Q1'26: +13.8% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+17.4% ★ Q1'26: +58.4% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+10.8% ★ Q1'26: +35.4% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.2% ★ Q1'26: -5.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.46× ★ Q1'26: 0.18× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
39.82B
est: 39.00B (+2.1%)
|
54.97B
est: 55.00B (0.0%)
|
52.59B
est: 53.30B (-1.3%)
|
66.20B
est: 60.00B (+10.3%)
|
72.80B
est: 73.00B (-0.3%)
|
144.13B
est: 134.30B (+7.3%)
|
157.71B
est: 203.90B (-22.7%)
|
118.08B
est: 253.30B (-53.4%)
|
134.22B
est: 134.00B (+0.2%)
|
138.16B
est: 149.00B (-7.3%)
|
162.02B
est: 171.00B (-5.3%)
|
196.00B
196.00B – 196.00B
+14.6% YoY
|
| EBITDA |
13.95B
est: 13.65B (+2.2%)
|
14.83B
est: 19.25B (-23.0%)
|
6.50B
est: 18.66B (-65.1%)
|
10.63B
est: 21.00B (-49.4%)
|
20.15B
est: 25.55B (-21.1%)
|
66.03B
est: 47.01B (+40.5%)
|
62.68B
est: 71.37B (-12.2%)
|
35.03B
est: 88.66B (-60.5%)
|
40.21B
est: 46.90B (-14.3%)
|
41.20B
est: 45.53B (-9.5%)
|
38.25B
est: 52.26B (-26.8%)
|
59.90B
59.90B – 59.90B
+14.6% YoY
|
| EBIT |
-832.24M
est: 11.61B (-107.2%)
|
12.39B
est: 16.37B (-24.4%)
|
-1.79B
est: 15.87B (-111.3%)
|
70.42M
est: 17.86B (-99.6%)
|
15.07B
est: 21.73B (-30.7%)
|
60.64B
est: 39.98B (+51.7%)
|
56.64B
est: 60.71B (-6.7%)
|
24.67B
est: 75.41B (-67.3%)
|
31.92B
est: 39.90B (-20.0%)
|
32.75B
est: 37.01B (-11.5%)
|
28.19B
est: 42.47B (-33.6%)
|
48.68B
48.68B – 48.68B
+14.6% YoY
|
| Net Income |
-1.97B
|
12.62B
est: 12.81B (-1.5%)
|
-2.15B
est: 7.17B (-129.9%)
|
-1.69B
est: 3.60B (-147.0%)
|
11.65B
est: 5.49B (+112.4%)
|
45.49B
est: 41.14B (+10.6%)
|
44.37B
est: 68.43B (-35.2%)
|
24.15B
est: 79.93B (-69.8%)
|
25.95B
est: 25.87B (+0.3%)
|
27.26B
est: 34.19B (-20.3%)
|
23.68B
est: 37.77B (-37.3%)
|
43.67B
43.67B – 43.67B
+15.6% YoY
|
| SGA |
3.83B
est: 6.91B (-44.6%)
|
6.38B
est: 9.74B (-34.6%)
|
6.94B
est: 9.44B (-26.5%)
|
6.77B
est: 10.63B (-36.3%)
|
5.77B
est: 12.93B (-55.4%)
|
17.40B
est: 23.79B (-26.9%)
|
28.87B
est: 36.12B (-20.1%)
|
27.01B
est: 44.87B (-39.8%)
|
33.64B
est: 23.74B (+41.7%)
|
14.17B
est: 26.52B (-46.5%)
|
20.22B
est: 30.43B (-33.6%)
|
34.88B
34.88B – 34.88B
+14.6% YoY
|
| EPS |
-87.26
|
548.51
est: 584.09 (-6.1%)
|
-93.23
est: 327.00 (-128.5%)
|
-73.35
est: 164.00 (-144.7%)
|
506.66
est: 250.00 (+102.7%)
|
1,978.15
est: 1,875.00 (+5.5%)
|
1,937.17
est: 3,119.00 (-37.9%)
|
1,079.94
est: 3,643.00 (-70.4%)
|
1,181.00
est: 1,179.00 (+0.2%)
|
1,242.40
est: 1,577.00 (-21.2%)
|
1,092.00
est: 1,742.00 (-37.3%)
|
2,014.00
2,014.00 – 2,014.00
+15.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-21 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-19 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-18 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-15 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-14 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-13 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-04 | A | 4/5 | 4/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 4/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets ex China Core Equity ETF DEXC | 0.00% | 10.5K | 0.56% |
| 2 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 39.7K | 0.46% |
| 3 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 140.4K | 0.39% |
| 4 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 83.5K | 0.29% |
| 5 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 53.4K | 0.28% |
| 6 | Invesco Dow Jones Islamic Global Developed Markets UCITS ETF IGDA.L | 0.00% | 2.2K | 0.40% |
| 7 | Avantis Emerging Markets Equity ETF AVEM | 0.00% | 6.7K | 0.33% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| EuiYeol Choi | CEO & Director | 990M | male |
| ByeongCheol Kim | Managing Director of Research & Development | — | male |
| Yoonseok Lee | Managing Director of Research & Development | — | male |
| Young-Min Kim | Managing Director of Product Management | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 206640.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
